Topic
Genomics
3 posts
PACB Stock: Is PacBio a Deep-Value Buy or a High-Risk Trap?
Analyzing PACB stock after its Q1 2026 earnings, high cash burn, and the global launch of SPRQ-Nx chemistry. Is PacBio poised for a contrarian recovery?
May 27, 2026·12 min read
ILMN Stock Forecast: The Post-Grail Turnaround in 2026
Analyzing ILMN stock in 2026? Discover how Illumina's financial turnaround, NovaSeq X rollout, and post-Grail strategy are shaping its stock outlook.
May 23, 2026·17 min read
Illumina Stock (ILMN): Is the Genomic Giant Finally a Buy?
Is Illumina stock a buy after raising its 2026 outlook? Explore our in-depth ILMN stock analysis covering Q1 earnings, China risks, and NovaSeq X growth.
May 22, 2026·12 min read